Astragaloside IV alleviates hypoxic pulmonary hypertension by inhibiting RELM-β to reduce PINK1/Parkin-mediated mitophagy in pulmonary artery smooth muscle cells (PASMCs).

IF 7.7 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Rongzhen Ding, Haiping Xie, Shuliu Sang, Li Qin, Yinhui Sun, Chao Zhang, Jian Yi, Hui Liu, Jianmin Fan, Guoran Peng, BeiBei Cheng, Lan Song, Aiguo Dai
{"title":"Astragaloside IV alleviates hypoxic pulmonary hypertension by inhibiting RELM-β to reduce PINK1/Parkin-mediated mitophagy in pulmonary artery smooth muscle cells (PASMCs).","authors":"Rongzhen Ding, Haiping Xie, Shuliu Sang, Li Qin, Yinhui Sun, Chao Zhang, Jian Yi, Hui Liu, Jianmin Fan, Guoran Peng, BeiBei Cheng, Lan Song, Aiguo Dai","doi":"10.1111/bph.70166","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>Hypoxic pulmonary hypertension (HPH) is a chronic disorder marked by irreversible pulmonary vascular remodelling (PVR) and pulmonary artery smooth muscle cell (PASMC) dysfunction. Astragaloside IV (AS-IV), a natural saponin from Astragalus, shows potential in HPH management. This study explores AS-IV's protective effect on PVR in HPH.</p><p><strong>Experimental approach: </strong>HPH mouse model was established by 28 days of hypoxia and AS-IV was administered daily. The effect of AS-IV on the HPH model was evaluated by haemodynamic parameters, echocardiography and pathological changes in the pulmonary arteries. In vitro, CCK8, EdU, scratch and transwell assays assessed cell proliferation and migration. Transmission electron microscopy, immunofluorescence and Seahorse XFe24 were employed to detect mitochondrial morphology and function. Retnlb<sup>-/-</sup> mice were constructed to assess the effect of RELM-β in HPH. The impact of AS-IV on RELM-β expression and mitophagy at the cellular level was evaluated through lentivirus overexpression.</p><p><strong>Key results: </strong>AS-IV ameliorated HPH in mice by reducing right ventricular systolic pressure (RVSP), attenuating right ventricular hypertrophy and inhibiting vascular remodelling. AS-IV improves hypoxia-induced proliferation, migration and phenotypic transformation of PASMC in vitro. AS-IV reduced hypoxia-induced increases in RELM-β, PINK1, Parkin and excessive mitophagy. Retnlb (RELM-β) knockdown amended mitophagy and PVR under hypoxia. However, the overexpression of RETNLB (RELM-β) hindered the regulatory effect of AS-IV on mitophagy mediated by PINK1/Parkin pathways.</p><p><strong>Conclusions and implications: </strong>AS-IV attenuated the hypoxia-induced increase of PASMC RELM-β expression and suppressed PINK1/Parkin-mediated mitophagy, resulting in the amelioration of PVR. This study unveils the potential of AS-IV as a therapeutic approach for HPH.</p>","PeriodicalId":9262,"journal":{"name":"British Journal of Pharmacology","volume":" ","pages":""},"PeriodicalIF":7.7000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bph.70166","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and purpose: Hypoxic pulmonary hypertension (HPH) is a chronic disorder marked by irreversible pulmonary vascular remodelling (PVR) and pulmonary artery smooth muscle cell (PASMC) dysfunction. Astragaloside IV (AS-IV), a natural saponin from Astragalus, shows potential in HPH management. This study explores AS-IV's protective effect on PVR in HPH.

Experimental approach: HPH mouse model was established by 28 days of hypoxia and AS-IV was administered daily. The effect of AS-IV on the HPH model was evaluated by haemodynamic parameters, echocardiography and pathological changes in the pulmonary arteries. In vitro, CCK8, EdU, scratch and transwell assays assessed cell proliferation and migration. Transmission electron microscopy, immunofluorescence and Seahorse XFe24 were employed to detect mitochondrial morphology and function. Retnlb-/- mice were constructed to assess the effect of RELM-β in HPH. The impact of AS-IV on RELM-β expression and mitophagy at the cellular level was evaluated through lentivirus overexpression.

Key results: AS-IV ameliorated HPH in mice by reducing right ventricular systolic pressure (RVSP), attenuating right ventricular hypertrophy and inhibiting vascular remodelling. AS-IV improves hypoxia-induced proliferation, migration and phenotypic transformation of PASMC in vitro. AS-IV reduced hypoxia-induced increases in RELM-β, PINK1, Parkin and excessive mitophagy. Retnlb (RELM-β) knockdown amended mitophagy and PVR under hypoxia. However, the overexpression of RETNLB (RELM-β) hindered the regulatory effect of AS-IV on mitophagy mediated by PINK1/Parkin pathways.

Conclusions and implications: AS-IV attenuated the hypoxia-induced increase of PASMC RELM-β expression and suppressed PINK1/Parkin-mediated mitophagy, resulting in the amelioration of PVR. This study unveils the potential of AS-IV as a therapeutic approach for HPH.

黄芪甲苷通过抑制RELM-β减少肺动脉平滑肌细胞(PASMCs)中PINK1/ parkin介导的有丝分裂来缓解缺氧性肺动脉高压。
背景与目的:低氧性肺动脉高压(HPH)是一种以不可逆肺血管重构(PVR)和肺动脉平滑肌细胞(PASMC)功能障碍为特征的慢性疾病。黄芪甲苷(AS-IV)是黄芪中的一种天然皂苷,具有治疗HPH的潜力。本研究探讨AS-IV对HPH患者PVR的保护作用。实验方法:缺氧28 d建立HPH小鼠模型,每日给予AS-IV。通过血流动力学参数、超声心动图及肺动脉病理变化评价AS-IV对HPH模型的影响。体外,CCK8、EdU、scratch和transwell检测评估细胞增殖和迁移。采用透射电镜、免疫荧光和海马XFe24检测线粒体形态和功能。构建Retnlb-/-小鼠,观察RELM-β对HPH的影响。通过慢病毒过表达来评估AS-IV在细胞水平上对RELM-β表达和有丝分裂的影响。关键结果:AS-IV通过降低右心室收缩压(RVSP)、减轻右心室肥厚和抑制血管重构来改善小鼠HPH。AS-IV在体外改善缺氧诱导的PASMC增殖、迁移和表型转化。AS-IV降低了缺氧引起的RELM-β、PINK1、Parkin和过度的线粒体自噬的增加。Retnlb (RELM-β)下调可改变缺氧条件下的线粒体自噬和PVR。然而,RETNLB (RELM-β)的过表达阻碍了AS-IV对PINK1/Parkin通路介导的线粒体自噬的调节作用。结论与意义:AS-IV可减弱缺氧诱导的PASMC RELM-β表达升高,抑制PINK1/ parkin介导的线粒体自噬,从而改善PVR。这项研究揭示了as - iv作为HPH治疗方法的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.40
自引率
12.30%
发文量
270
审稿时长
2.0 months
期刊介绍: The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries. Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues. In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信